TScan Therapeutics, Inc.
TCRX
$1.27
-$0.11-7.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 226.47% | -36.61% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 226.47% | -36.61% | |||
| Cost of Revenue | 140.72% | -378.54% | |||
| Gross Profit | -137.41% | 392.77% | |||
| SG&A Expenses | 7.60% | 8.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.79% | 11.01% | |||
| Operating Income | 1.26% | -12.54% | |||
| Income Before Tax | 4.70% | -19.81% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 4.70% | -19.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.70% | -19.81% | |||
| EBIT | 1.26% | -12.54% | |||
| EBITDA | 1.19% | -13.95% | |||
| EPS Basic | 58.41% | -12.96% | |||
| Normalized Basic EPS | 57.09% | -9.51% | |||
| EPS Diluted | 58.41% | -12.96% | |||
| Normalized Diluted EPS | 57.09% | -9.51% | |||
| Average Basic Shares Outstanding | 129.15% | 6.07% | |||
| Average Diluted Shares Outstanding | 129.15% | 6.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||